BAY 73-6691 – (794568-92-6)

BAY 73-6691 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor developed by Bayer for the treatment of Alzheimer’s disease. It is the first compound to selectively target the PDE9A enzyme, which is primarily expressed in the brain, particularly in regions like the cerebellum, neocortex, striatum, and hippocampus.

Preclinical studies have shown that BAY 73-6691 improves cognitive function in animal models, making it a promising candidate for Alzheimer’s research. However, its progression to human trials remains uncertain. The compound is also widely used in research to study PDE9A’s role in brain function.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/BAY_73-6691
https://pubchem.ncbi.nlm.nih.gov/compound/135541419
https://www.medchemexpress.com/BAY_73-6691.html
https://www.medkoo.com/products/9148
https://pubmed.ncbi.nlm.nih.gov/18674549/
https://www.sciencedirect.com/science/article/abs/pii/S0006899316302049